Head-To-Head Analysis: MeiraGTx (NASDAQ:MGTX) vs. Omeros (NASDAQ:OMER)

Omeros (NASDAQ:OMER – Get Free Report) and MeiraGTx (NASDAQ:MGTX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Valuation and Earnings

This table compares Omeros and MeiraGTx”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Omeros $38.42 million 31.43 -$3.35 million $1.28 13.03
MeiraGTx $81.39 million 10.49 -$114.20 million $0.80 10.92

Omeros has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Omeros and MeiraGTx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Omeros N/A -164.92% 69.41%
MeiraGTx 19.46% 85.23% 24.12%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Omeros and MeiraGTx, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros 0 2 3 0 2.60
MeiraGTx 0 3 5 0 2.62

Omeros currently has a consensus target price of $30.33, indicating a potential upside of 81.85%. MeiraGTx has a consensus target price of $24.00, indicating a potential upside of 174.60%. Given MeiraGTx’s stronger consensus rating and higher probable upside, analysts clearly believe MeiraGTx is more favorable than Omeros.

Institutional & Insider Ownership

48.8% of Omeros shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Omeros has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

About Omeros

(Get Free Report)

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.

About MeiraGTx

(Get Free Report)

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.